the first tests
The AVX/COVID-12 vaccine was tested in 91 healthy volunteers who participated in a first safety study. From that study, 30 people received the “Patria” doses. None presented serious adverse events (“those that cause death or serious deterioration of health”).
Twenty-nine of the 30 volunteers “experienced some type of mild discomfort associated with the vaccination, such as dizziness, headache, pain at the injection site, nausea, abdominal pain, diarrhea, chills, fatigue, muscle pain, sore throat, among others”, says the research protocol.
“14 out of 30 subjects had some discomfort of moderate intensity (discomfort that interrupts the daily routine, but without being disabling),” he adds. Only three of the participants had any event of severe intensity (feeling sleepy, abdominal pain, fatigue, menstrual cramps).
All the people recovered spontaneously without sequelae of any kind.
In a second ongoing study effort, more than 60 subjects with low antibody levels have received the AVX/Covid-12 vaccine. None presented reactions other than those reported in the phase I study.
(Graphic: Conacyt)
According to the researchers leading the process, the “Patria” vaccine will only be available for use within the protocol and subsequently “will depend on whether it is determined that it meets all the necessary criteria to be able to receive authorization for emergency use by the regulatory agencies”.
Each participant receives 500 pesos each time they attend the laboratory for check-ups and blood samples. The information she shares with the lab is kept private. At the end of the six months, you will be able to see the results of the study. In addition, you will be covered by health insurance, in case the vaccines cause an adverse reaction.
According to Conacyt, the Mexican vaccine generates a significant immune response in volunteers with previous immunity and provides protection against the SARS-CoV-2 virus as a booster.
